NSRX
HEALTHCARENasus Pharma Ltd
$3.14+0.26 (+9.03%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving NSRX Today?
No stock-specific AI insight has been generated for NSRX yet. Check back soon — insights are generated from recent news analysis.
0
Fundamentals
Market Cap$37M
P/E Ratio—
EPS$-0.72
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume146K
Avg Volume (10D)—
Shares Outstanding11.7M
NSRX News
20 articles- Nasus Pharma to Participate in Upcoming Investor ConferencesYahoo Finance·May 1, 2026
- RedChip's Biotech Virtual Investor Conference Replays Now AvailableYahoo Finance·Apr 21, 2026
- RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare PlatformsYahoo Finance·Apr 7, 2026
- Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business UpdateGlobeNewswire Inc.·Mar 25, 2026
- BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar TranscriptYahoo Finance·Mar 19, 2026
- NSRX: NS002 Phase II Topline ResultsYahoo Finance·Mar 16, 2026
- Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic ThresholdYahoo Finance·Mar 16, 2026
- Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingYahoo Finance·Mar 13, 2026
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thYahoo Finance·Mar 10, 2026
- Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical StudyYahoo Finance·Mar 9, 2026
- Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor ForumYahoo Finance·Mar 9, 2026
- Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026Yahoo Finance·Feb 17, 2026
- Nasus Pharma Announces Closing of $15.0 Million Private PlacementYahoo Finance·Feb 13, 2026
- Nasus Pharma Announces Pricing of $15.0 Million Private PlacementYahoo Finance·Feb 11, 2026
- Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine PowderYahoo Finance·Jan 20, 2026
- Nasus Pharma CEO Issues 2025 Letter to ShareholdersYahoo Finance·Dec 22, 2025
- Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial OfficerYahoo Finance·Nov 20, 2025
- Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant DosedYahoo Finance·Nov 18, 2025
- Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine PowderYahoo Finance·Nov 6, 2025
- Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine ProgramYahoo Finance·Oct 8, 2025
All 20 articles loaded
Price Data
Open$2.88
Previous Close$2.88
Day High$3.20
Day Low$2.88
52 Week High$9.99
52 Week Low$0.00
Fundamentals
Market Cap$37M
P/E Ratio—
EPS$-0.72
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume146K
Avg Volume (10D)—
Shares Outstanding11.7M
About Nasus Pharma Ltd
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company is headquartered in Tel Aviv-Yafo, Israel.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—